Partner With Us
Empower your patients with access to cutting-edge advancements in modern healthcare. Advanced stem cell therapies offer promising potential to treat and prevent a variety of conditions, including degenerative diseases, musculoskeletal injuries, and age-related frailty.
clinical trials
Access Stem Cell Treatments
Cellcolabs Clinical offers an exclusive opportunity for medical partners to give their patients access to advanced stem cell treatments through our patient-funded clinical trials in the Bahamas.
These trials are using certified GMP-grade Mesenchymal Stem Cells (MSCs) produced at Cellcolabs’ facility at the Karolinska Institute Campus in Sweden. MSCs hold significant potential across various indications, thanks to their unique ability to support and enhance the body’s natural healing processes.
Prevention of Cardiovascular Disease
This clinical trial investigates the potential of MSCs in prevention of cardiovascular disease and follows several longevity and disease biomarkers. This proactive approach to health care seeks to maintain health and prevent development of illness.
This trial is administered through systemic infusion (an IV).
Musculoskeletal Injuries
This clinical trial
investigates the use of MSCs in
addressing musculoskeletal
injuries and degeneration, which
may arise from accidents,
sports injuries, or physical
overexertion.
This trial is administered through local injections.
Collaborate With a Leading Global Partner
Cellcolabs provides high-quality MSCs sourced from the bone marrow of young, healthy, and voluntary donors, all of whom undergo rigorous pre-screening.
The manufacturing and handling of cells adhere to GMP (Good Manufacturing Practice) standards and is based on over 20 years of scientific research at the Karolinska Institute in Sweden.
Why Cellcolabs?
High-Quality Stem Cells
The manufacturing of cells has been optimised by over 20 years of scientific research at the world-renowned Karolinska Institute and is approved by the Swedish Medical Products Agency. The MSCs used in our trials are manufactured by Cellcolabs’ GMP (Good Manufacturing Practice)-certified environment for iATMP in Stockholm, Sweden.
The clinical trials have received approval by the National Stem Cell Ethics Committee in the Bahamas.
Safety Profile of MSCs
Mesenchymal Stem Cells derived from bone marrow have been rigorously studied and shown to have a favourable safety profile. A meta-analysis of 62 randomized clinical trials confirmed the safety of MSC treatments compared to placebos, with no serious adverse events reported.
A Simple Referral Process
Pricing
The treatments are participant-funded, with rates varying based on cell dose and method of administration.
Prices start from 16.500 USD per treatment.
Questions?
Partner with Cellcolabs to start referring your patients.
Get in touch with nina.leibenfrost@cellcolabs.com to find out more.